PharmacoEconomics & Outcomes News

, Volume 770, Issue 1, pp 31–31 | Cite as

UGT1A1*28 genotyping reduces irinotecan toxicity costs

Clinical study


  1. Roncato R, et al. Cost evaluation of irinotecan-related toxicities associated with the UGT1A1*28 patient genotype. Clinical Pharmacology and Therapeutics : 11 Jan 2017. Available from: URL:

Copyright information

© Springer International Publishing Switzerland 2017

Personalised recommendations